Enlivex Treasury Stock from 2010 to 2024
| ENLV Stock | USD 1.14 0.07 6.54% |
Treasury Stock | First Reported 2001-03-31 | Previous Quarter -1 M | Current Value -1 M | Quarterly Volatility 0.0 |
Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13.3 K, Total Revenue of 0.0 or Research Development of 20.2 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.58. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
Enlivex | Treasury Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.